

NEWS 25 AUG 25 CA/CAPLUS, CASREACT, and IFI and USPAT databases  
enhanced for more flexible patent number searching  
NEWS 26 AUG 27 CAS definition of basic patents expanded to ensure  
comprehensive access to substance and sequence  
information

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:56:51 ON 29 AUG 2008

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 11:57:08 ON 29 AUG 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
held by the publishers listed in the PUBLISHER (PB) field (available  
for records published or updated in Chemical Abstracts after December  
26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the  
American Chemical Society and is provided to assist you in searching  
databases on STN. Any dissemination, distribution, copying, or storing  
of this information, without the prior written consent of CAS, is  
strictly prohibited.

FILE COVERS 1907 - 29 Aug 2008 VOL 149 ISS 10  
FILE LAST UPDATED: 28 Aug 2008 (20080828/ED)

Caplus now includes complete International Patent Classification (IPC)  
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

10/923,271

<http://www.cas.org/legal/infopolicy.html>

=>


Uploading C:\Program Files\Stnexp\Queries\10587771.str

L1        STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1        STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 11:57:34 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -        1083 TO ITERATE

100.0% PROCESSED        1083 ITERATIONS

12 ANSWERS

SEARCH TIME: 00.00.01

L2        12 SEA SSS FUL L1

L3        6 L2

=> d 1-6 ibib abs hitstr

L3    ANSWER 1 OF 6    CAPLUS    COPYRIGHT 2008 ACS on STN



ACCESSION NUMBER:        2005:902849    CAPLUS

DOCUMENT NUMBER:        143:229575

TITLE:                    Preparation of amino-hydroxy-functionalized-aromatic  
carboxy compounds as calcilytic compounds useful

INVENTOR(S): against bone and mineral diseases  
 Marquis, Robert W., Jr.; Ramanjulu, Joshi M.  
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
 SOURCE: PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005077892	A1	20050825	WO 2005-US3499	20050204
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1713767	A1	20061025	EP 2005-712810	20050204
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS			
JP 2007523076	T	20070816	JP 2006-552249	20050204
PRIORITY APPLN. INFO.:			US 2004-542554P	P 20040206
			WO 2005-US3499	W 20050204
OTHER SOURCE(S):	CASREACT 143:229575; MARPAT 143:229575			
GI				




- AB Novel calcilytic compds. (inhibitors of Ca receptor activity) (shown as I; R1 = H, CN, and halogen; R2 = H, halogen, CN, NO<sub>2</sub>, and SO<sub>2</sub>R<sub>4</sub>; R3 = (un)substituted C0-6 alkyl, and C0-6 alkenyl; R4 = OH, (un)substituted OC1-7alkyl; NH<sub>2</sub>, and NHR<sub>4</sub>; R5 = aryl, fused aryl, dihydro, tetrahydro fused aryl, and heteroaryl, (un)substituted with OH, halogen, C1-4 alkyl, C1-4 alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, CN and NO; e.g. (E)-3-[3,4-difluoro-2-[[[(R)-2-hydroxy-3-[[2-(indan-2-yl)-1,1-dimethylethyl]amino]propyl]oxy]phenyl]-2-propenoic acid Et ester (shown as II)) and methods of using them are provided. No data is provided for the calcilytic activity of I. Although the methods of preparation are not claimed, 13 example preps. are included. For example, II was prepared in 4 steps (18, 87, 80, and 82 % yields) starting with bromination of 2,3-difluorophenol and involving intermediates 6-bromo-2,3-difluorophenol, (R)-2-[(6-bromo-2,3-difluorophenoxy)methyl]oxirane, and (R)-1-(6-bromo-2,3-difluorophenoxy)-3-[[2-(indan-2-yl)-1,1-dimethylethyl]amino]propan-2-ol.
- IT 862992-99-2P, 4-[3-Cyano-2-[[[(R)-2-hydroxy-3-[[2-(indan-2-yl)-1,1-dimethylethyl]amino]propyl]oxy]phenyl]butyric acid methyl ester  
862993-00-8P, 4-[3-Cyano-2-[[[(R)-2-hydroxy-3-[[2-(indan-2-yl)-1,1-dimethylethyl]amino]propyl]oxy]phenyl]butyric acid hydrochloride  
862993-07-5P, 4-[3-Cyano-2-[[[(R)-2-hydroxy-3-[[2-(indan-2-yl)-1,1-dimethylethyl]amino]propyl]oxy]phenyl]butyric acid  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of amino-hydroxy-functionalized-aromatic carboxy

compds. as calcilytic compds. useful against bone and mineral diseases)

RN 862992-99-2 CAPLUS

CN Benzenebutanoic acid, 3-cyano-2-[(2R)-3-[[2-(2,3-dihydro-1H-inden-2-yl)-1,1-dimethylethyl]amino]-2-hydroxypropoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 862993-00-8 CAPLUS

CN Benzenebutanoic acid, 3-cyano-2-[(2R)-3-[[2-(2,3-dihydro-1H-inden-2-yl)-1,1-dimethylethyl]amino]-2-hydroxypropoxy]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.

10/923,271




● HCl

RN 862993-07-5 CAPLUS

CN Benzenebutanoic acid, 3-cyano-2-[(2R)-3-[[2-(2,3-dihydro-1H-inden-2-yl)-1,1-dimethylethyl]amino]-2-hydroxypropoxy]- (CA INDEX NAME)

Absolute stereochemistry.



IT 862993-01-9P, 4-[3-Cyano-2-[[ (R)-2-hydroxy-3-[[2-(indan-2-yl)-1,1-dimethylethyl]amino]propyl]oxy]phenyl]butyric acid ethyl ester hydrochloride 862993-08-6P, 4-[3-Cyano-2-[[ (R)-2-hydroxy-3-[[2-(indan-2-yl)-1,1-dimethylethyl]amino]propyl]oxy]phenyl]butyric acid ethyl ester

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of amino-hydroxy-functionalized-aromatic carboxy compds. as calcilytic compds. useful against bone and mineral diseases)

RN 862993-01-9 CAPLUS

CN Benzenebutanoic acid, 3-cyano-2-[(2R)-3-[[2-(2,3-dihydro-1H-inden-2-yl)-1,1-dimethylethyl]amino]-2-hydroxypropoxy]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.

10/923,271




● HCl

RN 862993-08-6 CAPLUS

CN Benzenebutanoic acid, 3-cyano-2-[(2R)-3-[[2-(2,3-dihydro-1H-inden-2-yl)-1,1-dimethylethyl]amino]-2-hydroxypropoxy]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1986:515008 CAPLUS

DOCUMENT NUMBER: 105:115008

ORIGINAL REFERENCE NO.: 105:18619a,18622a

TITLE: Syntheses of carbon-14-labeled prizidilol dihydrochloride

AUTHOR(S): Saunders, D.; Warrington, B. H.

CORPORATE SOURCE: Smith Kline and French Res. Ltd., Welwyn/Hertfordshire, AL6 9AR, UK



SOURCE: Journal of Labelled Compounds and Radiopharmaceuticals (1985), 22(9), 869-81  
CODEN: JLCRD4; ISSN: 0362-4803

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 105:115008

GI




AB Two syntheses of radiolabeled prizidilol-2HCl are described. A ten-stage synthesis gave [3,6- $^{14}\text{C}_2$ ]prizidilol-2HCl I in an overall yield of 0.91%. A later, alternative procedure led to [4,5- $^{14}\text{C}_2$ ]prizidilol-2HCl II with an overall radiochem. yield of 8%.

IT 103913-02-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as intermediate for carbon-14-labeled prizidilol dihydrochloride)

RN 103913-02-6 CAPLUS

CN Benzenebutanoic-carboxy, $\gamma$ - $^{14}\text{C}_2$  acid, 2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]- $\gamma$ -oxo-, methyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1978:152654 CAPLUS

DOCUMENT NUMBER: 88:152654

ORIGINAL REFERENCE NO.: 88:24065a,24068a


TITLE: Dihydropyridazinones

INVENTOR(S): Coates, William John; Roe, Anthony Maitland; Slater,

10/923,271

PATENT ASSIGNEE(S): Robert Antony  
SOURCE: Smith Kline and French Laboratories Ltd., UK  
CODEN: BRXXAA  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1488330	A	19771012	GB 1973-58726	19731219
ZA 7407462	A	19751231	ZA 1974-7462	19741121
AU 7475724	A	19760527	AU 1974-75724	19741125
CA 1033733	A1	19780627	CA 1974-214774	19741127
IL 46158	A	19780831	IL 1974-46158	19741129
DK 7406340	A	19750825	DK 1974-6340	19741205
DK 142870	B	19810216		
DK 142870	C	19810921		
BE 823103	A1	19750609	BE 1974-151287	19741209
FI 7403569	A	19750620	FI 1974-3569	19741211
US 3931177	A	19760106	US 1974-531957	19741212
SE 7415691	A	19750623	SE 1974-15691	19741213
SE 411666	B	19800514		
SE 413405	C	19800911		
DE 2459468	A1	19750703	DE 1974-2459468	19741216
FR 2255070	A1	19750718	FR 1974-41471	19741217
FR 2255070	B1	19790921		
CH 608794	A5	19790131	CH 1974-16775	19741217
JP 50093984	A	19750726	JP 1974-146279	19741218
HU 170633	B	19770728	HU 1974-SI1445	19741218
SU 578872	A3	19771030	SU 1974-2088301	19741218
NL 7416578	A	19750623	NL 1974-16578	19741219
ES 433135	A1	19761116	ES 1974-433135	19741219
PRIORITY APPLN. INFO.: GI			GB 1973-58726	A 19731219



AB Forty title compds. I [R = H, alkyl, alkenyl, CF<sub>3</sub>, halo, cyano, NO<sub>2</sub>, OH, alkoxy, alkenyloxy, NH<sub>2</sub>, substituted amino; R<sub>1</sub> = H, Me; R<sub>2</sub> = Me<sub>2</sub>CH, Me<sub>3</sub>C; RR<sub>1</sub> = benzo; R<sub>3</sub> and R<sub>4</sub> (same or different) are H or Me] and their salts, useful as  $\beta$ -adrenergic blocking agents and antihypertensives (no data) were prepared Any I were prepared from RR<sub>1</sub>(HO)C<sub>6</sub>H<sub>2</sub>COCHR<sub>4</sub>CH<sub>2</sub>COR<sub>5</sub> (R<sub>5</sub> = OH, NH<sub>2</sub>, alkoxy, alkylamino) by treatment with an epihalohydrin, R<sub>2</sub>NH<sub>2</sub>,




and N2N4 or MeNHNH2. Thus, 6-[4-(2-hydroxy-3-isopropylaminopropoxy)phenyl]-4,5-dihydro-3(2H)-pyridazinone was prepared from 4-HOC6H4CO(CH2)2CONHMe by sequential treatment with epichlorohydrin, Me2CHNH2, and N2N4.

IT 59010-65-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and cyclocondensation of, with hydrazine)

RN 59010-65-0 CAPLUS

CN Benzenebutanoic acid, 2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]- $\beta$ -methyl- $\gamma$ -oxo-, methyl ester (CA INDEX NAME)




IT 56871-95-5P 56871-97-7P 56872-58-3P

59010-52-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as intermediate in aryldihydropyridazinone preparation)


RN 56871-95-5 CAPLUS

CN Benzenebutanoic acid, 2-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- $\gamma$ -oxo-, methyl ester (CA INDEX NAME)



RN 56871-97-7 CAPLUS


CN Benzenebutanoic acid, 2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]- $\gamma$ -oxo-, methyl ester (CA INDEX NAME)



10/923,271


RN 56872-58-3 CAPLUS

CN Benzenebutanoic acid, 5-(acetylamino)-2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]- $\gamma$ -oxo-, methyl ester (CA INDEX NAME)



RN 59010-52-5 CAPLUS

CN Benzenebutanoic acid, 4-chloro-2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]- $\gamma$ -oxo-, ethyl ester (CA INDEX NAME)



L3 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1977:423316 CAPLUS

DOCUMENT NUMBER: 87:23316

ORIGINAL REFERENCE NO.: 87:3697a,3700a

TITLE: Pharmaceutical compositions and methods of inhibiting  $\beta$ -adrenergic receptors

INVENTOR(S): Coates, William John; Roe, Anthony Maitland; Slater, Robert Antony

PATENT ASSIGNEE(S): Smith Kline and French Laboratories Ltd., UK

SOURCE: U.S., 15 pp. Division of U.S. 3,931,177.

CODEN: USXXAM

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 4011321	A	19770308	US 1975-613601	19750915
US 3931177	A	19760106	US 1974-531957	19741212
PRIORITY APPLN. INFO.:			US 1974-531957	A3 19741212
			GB 1973-58726	A 19731219


GI




- AB  $\beta$ -Sympatholytic and antihypertensive (no data) pyridazinones I [R = 2-, 3-, 4-OCH<sub>2</sub>CH(OH)CH<sub>2</sub>NHR<sub>2</sub>; R<sub>1</sub> = 3-allyl, 3-Cl, H, 3-OMe, 4-Me, 3-NO<sub>2</sub>, 5-NHAc; R<sub>2</sub> = CHMe<sub>2</sub>, CMe<sub>3</sub>] (13 compds.) were prepared. In successive reactions, 4-PhCH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>Br was subjected to Grignard reaction with N-methylsuccinimide, II treated with HBr, 4-HOC<sub>6</sub>H<sub>4</sub>COCH<sub>2</sub>CH<sub>2</sub>CONHMe treated with epichlorohydrin and Me<sub>2</sub>CHNH<sub>2</sub>, and 4-Me<sub>2</sub>CHNHCH<sub>2</sub>CH(OH)CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>COCH<sub>2</sub>CH<sub>2</sub>CONHMe treated with N<sub>2</sub>H<sub>4</sub> to give I [R = 4-OCH<sub>2</sub>CH(OH)CH<sub>2</sub>NHCHMe<sub>2</sub>].
- IT 56871-95-5P 56871-97-7P 56872-58-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and cyclization of, with hydrazine)
- RN 56871-95-5 CAPLUS
- CN Benzenebutanoic acid, 2-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- $\gamma$ -oxo-, methyl ester (CA INDEX NAME)



- RN 56871-97-7 CAPLUS
- CN Benzenebutanoic acid, 2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]- $\gamma$ -oxo-, methyl ester (CA INDEX NAME)



- RN 56872-58-3 CAPLUS
- CN Benzenebutanoic acid, 5-(acetylamino)-2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]- $\gamma$ -oxo-, methyl ester (CA INDEX NAME)



L3 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1976:164819 CAPLUS  
 DOCUMENT NUMBER: 84:164819  
 ORIGINAL REFERENCE NO.: 84:26766h,26767a  
 TITLE: 6-Hydrazinopyridazines  
 INVENTOR(S): Coates, William J.; Roe, Anthony M.; Slater, Robert A.; Taylor, Edwin Michael  
 PATENT ASSIGNEE(S): Smith Kline and French Laboratories Ltd., UK  
 SOURCE: Ger. Offen., 63 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2527066	A1	19760108	DE 1975-2527066	19750618
GB 1527712	A	19781011	GB 1974-26864	19740618
ZA 7503277	A	19760428	ZA 1975-3277	19750521
IL 47351	A	19800229	IL 1975-47351	19750526
AU 7581581	A	19761202	AU 1975-81581	19750527
DK 7502452	A	19751219	DK 1975-2452	19750530
DK 145099	B	19820830		
DK 145099	C	19830131		
US 4053601	A	19771011	US 1975-583379	19750603
BE 830158	A1	19751212	BE 1975-157265	19750612
CA 1067078	A1	19791127	CA 1975-229160	19750612
FI 7501790	A	19751219	FI 1975-1790	19750616
FI 62532	B	19820930		
FI 62532	C	19830110		
HU 175418	B	19800728	HU 1975-SI1472	19750616
SE 7506947	A	19751219	SE 1975-6947	19750617
SE 416650	B	19810126		
SE 416650	C	19810507		
JP 51013782	A	19760203	JP 1975-74260	19750617
CH 617429	A5	19800530	CH 1975-7871	19750617
NL 7507267	A	19751222	NL 1975-7267	19750618
FR 2275213	A1	19760116	FR 1975-19034	19750618
FR 2275213	B1	19790810		
ES 438685	A1	19770516	ES 1975-438685	19750618
SU 799661	A3	19810123	SU 1975-2145553	19750618
US 4111936	A	19780905	US 1977-816986	19770719
US 4111935	A	19780905	US 1977-816993	19770719
SU 862824	A3	19810907	SU 1978-2145553	19781222

10/923,271

PRIORITY APPLN. INFO.:

GB 1974-26864	A 19740618
GB 1975-20	A 19750102
GB 1975-2075	A 19750102
US 1975-583379	A2 19750603

OTHER SOURCE(S): MARPAT 84:164819  
GI




AB Vasodilating and  $\beta$ -sympatholytic (no data) hydrazinopyridazines I (R = CHMe<sub>2</sub>, CMe<sub>3</sub>) were prepared by esterifying 2-R1OC<sub>6</sub>H<sub>4</sub>CXCH<sub>2</sub>CH<sub>2</sub>COR<sub>2</sub> (II, R<sub>1</sub> = H, R<sub>2</sub> = OH, X = O), treating II (R<sub>1</sub> = H, R<sub>2</sub> = OMe, X = O) with epibromohydrin, treating II (R<sub>1</sub> = 2,3-epoxypropyl, R<sub>2</sub> = OMe, X = O) with RNH<sub>2</sub>, and treating II (R<sub>1</sub> = CH<sub>2</sub>CH(OH)CH<sub>2</sub>NHR, R<sub>2</sub> = OMe, X = O) with N<sub>2</sub>H<sub>4</sub>, brominating-dehydrobrominating II (R<sub>1</sub> = CH<sub>2</sub>CH(OH)CH<sub>2</sub>NHR, XR<sub>2</sub> = NNHCO) in the presence of HOAc-Ac<sub>2</sub>O, treating the pyridazinones III (X<sub>1</sub> = O) with P<sub>2</sub>S<sub>5</sub>, hydrolyzing III (X<sub>1</sub> = S) and treating with N<sub>2</sub>H<sub>4</sub>.

IT 56871-95-5P 56871-97-7P 56872-58-3P  
59010-52-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and condensation of, with hydrazine)


RN 56871-95-5 CAPLUS

CN Benzenebutanoic acid, 2-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- $\gamma$ -oxo-, methyl ester (CA INDEX NAME)



RN 56871-97-7 CAPLUS


CN Benzenebutanoic acid, 2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]- $\gamma$ -oxo-, methyl ester (CA INDEX NAME)



10/923,271


RN 56872-58-3 CAPLUS

CN Benzenebutanoic acid, 5-(acetylamino)-2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]- $\gamma$ -oxo-, methyl ester (CA INDEX NAME)



RN 59010-52-5 CAPLUS

CN Benzenebutanoic acid, 4-chloro-2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]- $\gamma$ -oxo-, ethyl ester (CA INDEX NAME)




IT 59010-49-0P 59010-65-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 59010-49-0 CAPLUS

CN Benzenebutanoic acid, 2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-4-methyl- $\gamma$ -oxo-, methyl ester (CA INDEX NAME)



RN 59010-65-0 CAPLUS

CN Benzenebutanoic acid, 2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]- $\beta$ -methyl- $\gamma$ -oxo-, methyl ester (CA INDEX NAME)



L3 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1975:564219 CAPLUS

DOCUMENT NUMBER: 83:164219

ORIGINAL REFERENCE NO.: 83:25775a,25778a

TITLE: Substituted aryldihydropyridazinones and their salts

INVENTOR(S): Coates, William J.; Roe, Anthony M.; Slater, Robert A.

PATENT ASSIGNEE(S): Smith Kline and French Laboratories Ltd., UK

SOURCE: Ger. Offen., 55 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2459468	A1	19750703	DE 1974-2459468	19741216
GB 1488330	A	19771012	GB 1973-58726	19731219
PRIORITY APPLN. INFO.:			GB 1973-58726	A 19731219

GI For diagram(s), see printed CA Issue.

AB Antihypertensive and  $\beta$ -sympatholytic pyridazinones I (X = p-C<sub>6</sub>H<sub>4</sub>, o-C<sub>6</sub>H<sub>4</sub>, 1,4-naphthalenediyl, 4-R<sub>1</sub>C<sub>6</sub>H<sub>3</sub>-m, 3-R<sub>1</sub>C<sub>6</sub>H<sub>3</sub>-p, 2-HOC<sub>6</sub>H<sub>3</sub>-m, 5-AcNHC<sub>6</sub>H<sub>3</sub>-o; R = CHMe<sub>2</sub>, CMe<sub>3</sub>; R<sub>1</sub> = allyl, Cl, OMe, Me, NO<sub>2</sub>) were prepared. Thus N-methylsuccinimide was subjected to Grignard reaction with 4-PhCH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>Br, 2-(4-benzyloxyphenyl)-2-hydroxy-1-methyl-5-pyrrolidinone dehydrated and hydrolyzed to 4-HOC<sub>6</sub>H<sub>4</sub>COCH<sub>2</sub>CH<sub>2</sub>CONHMe, which was treated with epichlorohydrin to give 3-[4-(2,3-epoxypropoxy)benzyl]-N-methylpropionamide. Reaction of the epoxy compound with Me<sub>2</sub>CHNH<sub>2</sub> gave 4-Me<sub>2</sub>CHNHCH<sub>2</sub>CH(OH)CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>COCH<sub>2</sub>CH<sub>2</sub>CONHMe, which was cyclized with N<sub>2</sub>H<sub>4</sub> to I (X = p-C<sub>6</sub>H<sub>4</sub>, R = CHMe<sub>2</sub>).


IT 56871-95-5P 56871-97-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and condensation of, with hydrazine)

RN 56871-95-5 CAPLUS


CN Benzenebutanoic acid, 2-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- $\gamma$ -oxo-, methyl ester (CA INDEX NAME)

10/923,271



RN 56871-97-7 CAPLUS

CN Benzenebutanoic acid, 2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]- $\gamma$ -oxo-, methyl ester (CA INDEX NAME)



IT 56872-58-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and reaction of, with hydrazine)

RN 56872-58-3 CAPLUS

CN Benzenebutanoic acid, 5-(acetylamino)-2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]- $\gamma$ -oxo-, methyl ester (CA INDEX NAME)

